Loading
A phase 2 trial of serplulimab in colorectal cancer, run by Fudan University, now recruiting.
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy is a phase 2, randomised interventional study registered as NCT07604909 by Fudan University, with a registry enrolment figure of 40 participants, started 2026-05-10 and due to reach its primary completion in 2027-09-10. Interventions recorded: Serplulimab; Second-Line Chemo/Targeted Therapy. Conditions listed: Colorectal Cancer; Relapse. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "Histologically confirmed early relapse (within 1 year after surgery, UICC stage IV) of colorectal cancer after adjuvant chemotherapy, with initially unresectable metastatic lesions or refusal of surgery". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/